Abstract:Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. At the time of diagnosis, it is often already advanced or metastatic, resulting in poor treatment outcomes. Treatment of NSCLC mainly relies on surgery, radiation and chemotherapy, but the survival rate has not increased significantly in the past decade. Therefore, finding appropriate treatment methods is necessary and crucial. Radiotherapy (RT) is a frequently employed approach for tumor treatment and serves as the primary local treatment for NSCLC. However, it often results in a poor prognosis and severe side effects when administered at high-dose irradiation. Existing literature suggests that RT may trigger the expression of nuclear factor kappa B (NF-ΚB), potentially compromising its therapeutic efficacy. Consequently, the question remains: Can targeting NF-ΚB signaling enhance the sensitivity of RT in NSCLC Furthermore, studies have indicated that elevated levels of CXCR5 in NSCLC contribute to tumor growth. CXCR5 is situated upstream of the NF-ΚB pathway. As a result, it becomes imperative and indispensable to develop strategies targeting the CXCL13/CXCR5/NF-ΚB signaling axis to counteract NSCLC growth. Lenvatinib is a multi-kinase inhibitor targeted drug. It has been proven to inhibit VEGFR1-3, FGFR1-4 and PDGFR, inhibiting tumor growth. Lenvatinib has received clinical approval from the US FDA for the treatment of advanced hepatocellular carcinoma (HCC) and has been shown to inhibit NF-ΚB expression in HCC. However, the potential radiation-sensitizing mechanism of Lenvatinib in lung cancer remains unexplored. This study is dedicated to investigating the effects and molecular mechanisms of combining Lenvatinib with radiotherapy in NSCLC. Our results suggest that lenvatinib may enhance the sensitivity of NSCLC to RT. Furthermore, evidence from both the intrinsic and extrinsic apoptosis pathways (Caspase-3/Caspase-8/Caspase-9) and TUNEL experiments supports the idea that the combined treatment of lenvatinib with RT induces a more pronounced apoptotic response compared to individual treatments. Additionally, silencing CXCR5 in NSCLC also appears to enhance its responsiveness to RT. In our western blot (p-ATM, p-CHK2), flow cytometry (p-ATM), we showed that the combination of lenvatinib and RT may effective induce DNA damage. Our in vivo data demonstrates that the combination of Lenvatinib and RT exhibits superior tumor growth inhibition. Immunohistochemistry (IHC) staining of tumor tissue also revealed an upregulation of apoptosis-related proteins and the downregulation of CXCL13/CXCR5/NF-ΚB related proteins. In conclusion, our findings suggest that Lenvatinib can serve as a radiosensitizer, enhancing the sensitivity of NSCLC patients to radiotherapy by targeting the CXCL13/CXCR5/NF-ΚB signaling pathway. Citation Format: Tsai-Lan Liao, I-Tsang Chiang, Bo-Han Huang, Fei-Ting Hsu, Ming-Hsien Chan. Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-ΚB axis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 695.

[A mechanistic study of radiotherapy on intratumoral NK cell infiltration augmentation by regulating the EZH2/CXCL10 pathway in hepatocellular carcinoma cells]

Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients.

Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma

Combined use of NK cells and radiotherapy in the treatment of solid tumors

Harnessing NK cell-based immunotherapy to prevent the high-dose radiotherapy-inducing tumor survival recurrence

Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS–STING pathway in hepatocellular carcinoma

Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6/CXCR2 in Hepatocellular Carcinoma

The Invasive Potential of Hepatoma Cells Induced by Radiotherapy is Related to the Activation of Hepatic Stellate Cells and Could be Inhibited by EGCG Through the TLR4 Signaling Pathway

The effects of stereotactic body radiotherapy on peripheral natural killer and CD3+CD56+ NKT-like cells in patients with hepatocellular carcinoma

EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner

CDX2 Enhances Natural Killer Cell-Mediated Immunotherapy Against Head and Neck Squamous Cell Carcinoma Through Up-Regulating CXCL14

Abstract 695: Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-ΚB axis

RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis

Tumor-associated NK cells facilitate tumor growth via NKp46 in immunocompetent murine hepatocellular carcinoma

Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting

Overexpressed Cxcr4 And Ccr7 On The Surface Of Nk92 Cell Have Improved Migration And Anti-Tumor Activity In Human Colon Tumor Model

Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma

Combination of IL-12 and radiotherapy induced regression of large orthotopic liver cancers through modulation of immune cells in tumor microenvironment

Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy